Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
We dont yet know who will be eligible and its unlikely to be available over the counter
doi: 10.2147/DMSO.S253097 182 ScottLJ
Previously, administration of GC via oral, rectal, IV and IM routes was prohibited in-competition due to clear evidence of systemic effects however this ban has now been extended to include any in-competition injection of GC (e.g., intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g., intrakeloid), intradermal, and subcutaneous)
But wait, theres more